What to Expect From Baxalta Q4 Earnings
Baxalta is scheduled to report fourth-quarter and full-year results before markets open on Tuesday.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Baxalta Inc. (NYSE: BXLT) is scheduled to report fourth-quarter and full-year results before markets open on Tuesday. The hematology and immunology focused biopharmaceutical company is expected to post earnings per share (EPS) of $0.56 and revenues of $1.71 billion for the quarter, as well as full-year EPS of $2.07 on revenues of $6.17 billion.
Baxalta, which was spun out of Baxter International Inc. (NYSE: BAX) last July, reported per-share earnings of $0.56 back in the third quarter, which handily exceeded analysts’ expectations. Guidance at the time called for EPS of $0.55 to $0.57 for the fourth quarter.
The big news for Baxalta is that last month it finally agreed to merge with U.K.-based Shire PLC (NASDAQ: SHPG) in a deal worth around $32 billion. Shire first made a bid for Baxalta on August 4, but Baxalta said that bid was too low. The deal now is expected to close in mid-2016.
Back in December of 2015, Baxalta announced it had received a key U.S. Food and Drug Administration (FDA) approval for its drug that treats von Willebrand disease, a rare inherited bleeding disorder that results from a missing protein. The company plans to launch the drug under the brand name Vonvendi, expanding its portfolio of treatments for bleeding disorders, led by the hemophilia treatments Advate and Feiba.
[recirclink id=314952]
In November, Baxalta won FDA approval for Adynovate, a long-acting version of Advate poised to contend with a new therapy from Biogen and in-development products from Bayer and Novo Nordisk. Baxalta set a very ambitious goal of launching 20 new products by 2020, with the intent to grow its annual revenue to $8.5 billion in the process.
Shares of Baxalta closed most recently at $38.67, in a 52-week trading range of $29.83 to $42.38. The consensus price target is $46.50, yielding an implied upside of almost 17%.
Contact [email protected] for any questions or corrections.
Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.
Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.
Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.
Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.
